Biodefense refers to the measures taken to restore the biosecurity of a group of organisms that are or may be exposed to biological threats or infectious diseases. It is an effective public health system with strong disease surveillance and rapid action to combat biological threats, limit the spread of disease, and provide medical care. The growth of the market is attributed to some key factors such as the existence of favorable government initiatives, the increase in the number of naturally occurring outbreaks, the increasing threat from biological weapons and nuclear-armed ICBM. However, little government R&D funding in developing and underdeveloped economies is expected to inhibit the growth of the biological defense market in the forecast years.
The Biodefense market is projected to reach $ 8,350.74 million in 2027 from $ 4,108.24 million in 2019. The market is expected to grow at a CAGR of 9.4% from 2020 to 2027.
A sample PDF copy together with the table of contents is available from: https://www.theinsightpartners.com/sample/TIPRE00005377/
Alnylam Pharmaceuticals, Inc.
Emergent BioSolutions Inc.
Cleveland Bio Labs
Elusys Therapeutics, Inc.
The Biological Defense market is segmented into Anthrax, Smallpox, Botulism, Radiation / Nuclear, and others by product. In 2019, the anthrax segment had the largest market share in the global biodefense market. The segment is expected to continue its dominance over the forecast period as governments of other countries increasingly provide funding for the development and stockpiling of adequate anthrax vaccines, primarily through various initiatives such as the BioShield Act, the Biomedical Advanced Research and Development Authority (BARDA) ) and the Executive Office of the Joint Chemical and Biological Defense Program.
While the government engages in these present and future policy activities and understands existing biosecurity and bio-defense policies, the pharmaceutical companies operating in the bio-defense market have significant opportunities to expand and be prepared for any bio-terrorism. For example, antibiotic developer Spero Therapeutics has received $ 15.7 million in research funding from the Biomedical Advanced Research and Development Authority for its oral carbapenem class candidate SPR994 to test the drug’s effectiveness against biological threats such as anthrax To evaluate plague and melioidosis. In addition, the Biomedical Advanced Research and Development Authority includes provisions for up to $ 28.5 million over five years and will support Spero’s clinical development of SPR994 for complicated urinary tract infections caused by drug-resistant bacteria. Government initiatives around the world are opening up new opportunities for bio-defense companies.
Improving Influenza Vaccines and Health Security is the budget that supports Executive Ordinance 13887, “Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health,” by increasing $ 95 million over the year Health and Health Level Adopted in 2020 will provide Human Services (HHS) for infrastructure and innovation in influenza vaccine manufacturing; advanced research and development of improved vaccines, therapeutics and diagnostics; international pandemic preparedness; and improved vaccine coverage across the country. The budget also funds the procurement of biological defense and emergency preparedness for HHS through the BioShield program and the Strategic National Stockpile. It includes $ 175 million in support of the CDC’s global health security activities, an increase of $ 50 million from the level set in 2020.
Global Biodefense Market – By Product
Radiation / Nuclear
Biodefense Market – By Geography
Rest of Europe
Rest of the Asia Pacific
Middle East and Africa
Rest of the Middle East and Africa
Request for discount at: https://www.theinsightpartners.com/discount/TIPRE00005377/
The Insight Partners is a one-stop industry researcher for actionable information. We help our clients find solutions to their research needs through our syndicated and consultative research services. We specialize in life sciences, technology, healthcare, manufacturing, automotive and defense, food beverages, chemistry, etc.
Call: + 1-646-491-9876
E-Mail: [email protected]